Price
90.05
-1.96%52W Range
Market Cap
₹92.69 Cr
Traded: ₹0.00 Cr (0.00%) 0.0x
Free Float: ₹15.40 Cr (0.02% of FF traded)
Volume · 60D trend
300 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | -- | -- | +67.0% | -- |
| Profit | -- | -- | -- | -- | +177.0% | -- |
| Return | -- | +33.0% | +60.0% | +123.0% | -- | Accelerating |
| ROE | -- | -- | -- | -- | -- | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Jun 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|
| Sales | 5 | 6 | 5 | 6 | 5 | 4 | 3 |
| Expenses | 5 | 5 | 5 | 5 | 4 | 4 | 3 |
| Operating Profit | 1 | 1 | 1 | 1 | 0 | -0 | -0 |
| OPM % | 12.9% | 15.9% | 11.1% | 20.6% | 5.6% | -5.5% | -16.1% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 0 | 1 | 0 | -1 | -1 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | 0 | 1 | 0 | 1 | 0 | -1 | -1 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.4 | 0.7 | 0.3 | 1.0 | 0.1 | -0.5 | -0.7 |
| Sales Growth (YoY) | 13.2% | 51.3% | -- | -- | 78.5% | -- | -- |
| Sales Growth (QoQ) | -9.2% | 6.8% | -12.5% | 33.2% | 21.5% | 46.9% | -- |
| OP Growth (YoY) | 161.5% | 538.1% | -- | -- | 161.9% | -- | -- |
| OP Growth (QoQ) | -26.1% | 53.3% | -52.8% | 388.5% | 223.8% | -- | -- |
| Profit Growth (YoY) | 740.0% | 236.0% | -- | -- | 107.0% | -- | -- |
| EPS Growth (YoY) | 720.0% | 234.7% | -- | -- | 107.1% | -- | -- |
| EPS Growth (QoQ) | -37.9% | 120.0% | -68.8% | 1820.0% | 110.2% | 30.0% | -- |
| OP Margin | 12.9% | 15.9% | 11.1% | 20.6% | 5.6% | -5.5% | -16.1% |
| Net Margin | 8.0% | 11.8% | 5.7% | 16.0% | 1.1% | -13.1% | -27.7% |
| Material Cost % | 17.1% | 15.1% | 15.7% | 17.8% | 19.0% | 18.9% | 19.6% |
| Employee Cost % | 36.0% | 33.6% | 36.4% | 28.3% | 35.8% | 42.9% | 50.4% |
| P/S | 4.10 | -- | -- | -- | -- | -- | -- |
| P/E | 38.65 | -- | -- | -- | -- | -- | -- |
| P/B | 12.82 | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Publication for the Financial Result as on 30 June 2026
Outcome of Board Meeting held on 12th August 2026
Unaudited Standalone Financial Results for quarter ended 30 June 2026
1. Board approved the appointment of Mr. Vaibhav Odhekar as Additional Executive Director with immediate Effect. 2. Board Approved the regularization of Mr. Vaibhav Odhekar as Executive ....
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....
Mr. Vaibhav Odhekar has resigned from Company as an Additional Executive Director with effect from close of business hours 25.07.2026
Resignation of Mr. Vaibhav Odhekar as an Additional Executive Director from Company with effect from close of business hours on 25.07.2026
Compliance Certificate in accordance with regulation 74(5) of SEBI (DP) regulation 2018 for quarter ended 30th June 2026
Intimation of closure of Trading window for quarter ended 30.06.2026
Intimation of Classification of Mr. Nikunj Mange and Mr. Jay Arvind Bhanushali as Promoters of the Company Pursuant to Completion of Open Offer
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shraddha Bhanushali & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepali Arvind Bhanushali & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raj Arvind Bhanushali & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nikunj Mange & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali & PACs
The Annual Secretarial Compliance Report for the year ended 31 March 2026 issued by Ms. Prajakta V. Padhye, Partner of Nilesh A. Pradhan & Co. LLP, Practising Company Secretaries, Mumbai
Newspaper Advertisement for the Financial Result as on 31 March 2026
Outcome of the Board Meeting dated May 23, 2026
Appointment of Mrs. Neetu Maurya as Company Secretary of the Company With Effect From 24.05.2026
The Board approved the appointment of Mr. Vaibhav Odhekar as an Additional Executive Director for 5 years
Appointment of M/s. Vishal J Bhanushali & Associates, as an Internal Auditor for F.Y. 2026-27 of the Company
The disclosure regarding of Mrs. Neetu Maurya as a Company Secretary of the company with effect from 24.05.2026 was inadvertently filed under change in Control
Board Meeting outcome for Dated May 23, 2026
Integrated Financial Results as on March 31, 2026
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Post-Offer Advertisement for the attention of the Equity Shareholders of the Aspira Pathlab & Diagnostics ....
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve Audited Standalone ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Compliance Certificate in accordance with Regulation 74(5) of SEBI (DP) Regulations, 2018 For quarter ended 31 March 2026
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Pre-Offer Advertisement and Corrignendum to the Detailed Public Statement under Regulation 18(7) in terms ....
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Recommendation of the Independent Director Committee ('IDC') in relation to the Open Offer ('Offer') to ....
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer to the Public Shareholders of Aspira Pathlab & Diagnostics Ltd ("Target Company").
Intimation of Closure of Trading Window
Aftertrade Broking Pvt Ltd ("Manager to the Offer") has informed BSE regarding Intimation of Identified Date for the Proposed Open Offer of Aspira Pathlab & Diagnostics Ltd ('Target Company') ....
Resignation of Ms. Krupali Shah from the post of Company Secretary cum Compliance Officer of the Company.
Newspaper Advertisement regarding Special Window Re-Lodgement for Transfer & Dematerialisation of Physical Securities.
Newspaper Publication for Unaudited Standalone Financial Results for the third quarter & nine months ended on 31.12.2025
Q3/2025-26 Financial Results
Approval of the Unaudited Standalone Financial Results for third quarter and nine months ended on December 31, 2025
Outcome of Postal Ballot
Voting Results & Scrutinizer Report of Postal Ballot conducted by remote e-voting process.
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Compliance Certificate under reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2025
Newspaper Publication-Postal Ballot
Intimation of Postal Ballot Notice for appointment of Mrs. Kiran Awasthi (DIN:09066721) as an Independent Director for the first term of 5 consecutive years
Revised disclosure pertaining to the demise of Dr. Alaka Keshav Deshapande ,pursuant to the observation email received from BSE
Demise of Independent Director - Dr. Alaka Keshav Deshpande (DIN:11238406)
Intimation of Closure of Trading Window for the quarter ended December 31, 2025.
Newspaper Publication of Standalone Financial Results for the quarter and half year ended September 30, 2025
Appointment of Mrs. Kiran Raghavendra Awsathi (DIN:09066721) as Additional Independent Director subject to the members approval.